# IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

> **NCT03401073** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Small Fiber Neuropathy
- Idiopathic Peripheral Neuropathy

## Interventions

- **DRUG:** Intravenous immunoglobulin
- **DRUG:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT03401073
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401073, "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03401073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*